ZRANB2-DT: A Potential Drug Target and Biomarker (G100852410)

Target Name: ZRANB2-DT

NCBI ID: G100852410

ZRANB2-DT

Other Name(s): ZRANB2-AS2 | ZRANB2 divergent transcript

ZRANB2-DT: A Potential Drug Target and Biomarker

Zinc finger RNA binding proteins (ZFPs) are a family of transmembrane proteins that play a crucial role in gene regulation. ZRANB2, a ZFP, is a potential drug target and biomarker that has been identified as a potential therapeutic target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Potential Drug Target

ZRANB2 is a protein that is expressed in various tissues and cells, including the brain, pancreas, and testes. It is known to play a role in the regulation of gene expression and has been shown to be involved in the development and progression of various diseases.

One of the potential drug targets for ZRANB2 is the regulation of its expression. By inhibiting the activity of ZRANB2, researchers have found that they can reduce the production of proteins that are involved in cancer progression, neurodegenerative diseases, and autoimmune disorders.

Potential Biomarker

In addition to its potential as a drug target, ZRANB2 has also been identified as a potential biomarker for several diseases. For example, ZRANB2 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Research has also shown that ZRANB2 is involved in the regulation of pancreatic cancer development and progression. By inhibiting the activity of ZRANB2, researchers have found that they can reduce the production of proteins that are involved in pancreatic cancer growth and progression.

Implications for Cancer Treatment

The potential drug target for ZRANB2 makes it an attractive target for cancer treatment. By inhibiting the activity of ZRANB2, researchers have found that they can reduce the production of proteins that are involved in cancer growth and progression.

One of the challenges in cancer treatment is the development of resistance to drugs, which can limit the effectiveness of current treatments. By targeting ZRANB2, researchers may be able to develop new treatments that are less likely to be affected by resistance.

Conclusion

ZRANB2 is a ZFP that has been shown to play a crucial role in the regulation of gene expression and the development and progression of various diseases. As a potential drug target and biomarker, ZRANB2 is a promising target for cancer treatment. Further research is needed to fully understand the role of ZRANB2 in disease and to develop effective treatments.

Protein Name: ZRANB2 Divergent Transcript

The "ZRANB2-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZRANB2-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets